Trial reportCancer2025
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial.
Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02766270 (A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
Who cites it
1 citing paper in PubMed.
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGiven the poor prognosis of IDH wild-type (IDH-wt) and telomerase reverse transcriptase promoter mutation (TERTp-mut) histological grade 2 to 3 gliomas, the World Health Organization has reclassified it as molecular glioblastoma. However, the effectiveness of chemoradiotherapy (CRT) in these patients remains unclear, especially in comparison to radiotherapy alone (RT). This study aims to assess CRT's efficacy in this population.
methodsA prospective randomized study was conducted at Beijing Tiantan Hospital from 2016 to 2019, enrolling 37 patients with histologically confirmed grade 2/3 IDH-wt/TERTp-mutant gliomas. Patients were randomly assigned to receive either RT (n = 18) or CRT (n = 19). After preliminary analysis showed a significant overall survival (OS) benefit in the CRT group, the study cohort was expanded from 2020 to 2022 by recruiting an additional 21 patients who all received CRT. Primary endpoints were OS and progression-free survival (PFS).
resultsThe final cohort comprised 58 patients (RT, 18; CRT, 40) with a median follow-up of 43.7 months (range, 7.9-75.1). CRT significantly improved OS compared to RT alone, with a median OS of 25.8 versus 17.2 months (hazard ratio, 0.31; 95% CI, 0.16-0.62; p = .001) and 2-year OS rate of 63.0% versus 16.7%. PFS also favored CRT, showing median PFS of 14.2 versus 7.1 months (hazard ratio, 0.38; 95% CI, 0.21-0.70; p = .002) and 1-year PFS rate of 56.6% versus 33.3%. Multivariable analysis confirmed CRT benefits were independent of O6-methylguanine-DNA methyl-transferase (MGMT) status (OS, p = .001; PFS, p = .002). Treatment was well-tolerated with no grade ≥3 toxicities in the CRT group.
conclusionCRT significantly improves survival in IDH-wt/TERTp-mut grade 2 to 3 gliomas with favorable safety. CLINICAL
trial registrationTrial registry name: CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas. Registration identification number: NCT02766270. URL for the registry: https://clinicaltrials.gov/study/NCT02766270?cond=NCT02766270&rank=1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.